Sanger Science

  • 8 August 2024

    Scientists and parents involved with a pioneering childhood cancer charity recently came together to discuss the future of research into the childhood cancer rhabdomyosarcoma, from its genetic causes to treatment innovations. A promising new project - co-designed by researchers and families - will now mine hundreds of biobank samples to understand the genomic and demographic factors governing how a child responds to treatment.

  • 1 May 20133.4 min read

    1 May 2013: Using attractive magnetic beads to capture Chlamydia from clinical samples is a rapid and effective way to harvest this bacteria (and it's DNA) for sensitive diagnosis and tracking

  • 25 April 20133.5 min read

    25 April 2013: In a break from our traditional blog style, we celebrate the 60th anniversary of Crick and Watson’s discovery of the structure of DNA by taking a light-hearted look at some of major scientific breakthroughs over the past six decades.

  • 23 April 20134.2 min read

    23 April 2013: ‘How much ‘creative licence’ should scientists allow creatives?’ asks Darren Logan, a Faculty member of the Sanger Institute. In his blog he explains how mentoring a genetics-based computer game completely changed his mind

  • 4 April 20133.4 min read

    4 April 2013: Mycobacterium abscessus infection is on the rise in CF patients. Josie Bryant talks about her research tracking the transmission of this bacterium in patients which has led to changes in infection control procedures in Papworth Hospital.

  • 27 March 20133.2 min read

    27 March 2013: Steven Witte explains how his fascination with the cause of autoimmune diseases such as arthritis has brought him to the Sanger Institute to study the effects of non-coding DNA [Image credit: ESA/Hubble]

  • 12 March 20134.8 min read

    13 March 2013: Tapeworm’s leave all the hard work to their hosts. But their laziness could be their undoing. Genome sequencing has revealed that the parasites' genetic simplicity makes them extremely reliant on certain genes and processes to live, and these 'weak spots' may be vulnerable to existing drugs